FLAG SEC filings, in plain English
Everything First Light Acquisition Group, Inc. has filed with the SEC that we hold — 40 filings, newest first, 7 with a plain-English summary of what changed and why it matters. Every row links to the primary document on EDGAR, so you can check the source rather than trust us.
The feed
live EDGAR captureNew filings appear here within minutes of hitting EDGAR; summaries follow once the pipeline has read them.
What changed: Q2 2026 10-Q of Calidi Biotherapeutics, Inc. (NYSE American: CLDI). An explanatory note states the company effected a 1-for-16 reverse stock split on July 30, 2026, combining every sixteen shares into one with fractional shares rounded up, reducing shares outstanding as of June 30, 2026 from 33,471,951 to approximately 2,092,023 including 9,375 non-voting escrow shares; authorized shares remain 330,000,000 and split-adjusted trading began July 31, 2026. Why it matters: All per-share history in the report is restated for the July 2026 1-for-16 split, so the prior-year $(31.75) loss per share is not comparable to anything previously published on a pre-split basis. Cash of $4.1 million stands against a quarterly operating loss of $4.2 million.
combination deadline, going-concern doubtnothing moved · 2 with no prior record of ours
- Combination deadline
- not previously extracted2026-09-30
- Going-concern doubt
- stated · unchanged
The clause “Termination Date, as such term is defined in the Warrant, from July 8, 2026 to September 30, 2026; New Facility Lease On July 10, 2026, we entered into a new lease agreement (the “New Lease”) for approximately 9,038 rentable square feet”…
The clause “The Company estimates that based on the Company’s liquidity resources, there is substantial doubt about the Company’s ability to continue as a going concern within 12 months from the date of issuance of these unaudited condensed”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
What changed: Exhibit 99.1 to an 8-K of Calidi Biotherapeutics, Inc. (NYSE American: CLDI): an August 13, 2026 press release reporting Q2 2026 results. Net loss attributable to common stockholders was $4.2 million, or $(2.94) per share, versus $5.7 million, or $(31.75) per share, a year earlier, with prior-period per-share amounts adjusted for the 1-for-16 reverse stock split completed in July 2026. R&D was $2.6 million, unchanged year over year, and G&A was $1.6 million versus $3.1 million, a $1.5 million or 48% reduction. Why it matters: The Q1 2027 first-patient-dosing target is a company plan following a pre-IND meeting, not a cleared IND. Cash of $4.1 million covers roughly one quarter at the reported loss rate.
What changed: Calidi Biotherapeutics, Inc., the First Light Acquisition Group successor, effected a 1-for-16 reverse stock split of its common stock, approved by stockholders at the annual meeting on June 12, 2026. The split became effective on July 30, 2026 and the shares began trading split-adjusted at the open on July 31, 2026 under the existing symbol CLDI, with a new CUSIP number 320703 507. Each holder's shares were exchanged for their prior holding divided by sixteen. The stated purpose is to raise the per-share trading price and support continued listing on NYSE American. Why it matters: This is a pre-emptive split — the company describes it as a proactive measure to reduce the risk of falling below NYSE American continued listing standards rather than a response to a deficiency notice already received. That is a better position than the cure-period splits elsewhere in this cohort, but the underlying signal is the same: a share price low enough that a sixteen-fold consolidation was needed. The company gives no assurance the effect will be achieved or sustained.
What changed: Calidi Biotherapeutics, Inc., the First Light Acquisition Group successor, entered a new lease on July 10, 2026 with BP3-SD4 5580 Morehouse Drive LLC for approximately 9,038 rentable square feet of office and laboratory space in San Diego. The landlord is an affiliate of the landlord under the existing lease being terminated. It estimates savings of about $1.1 million a year in rent and facility costs. The term is 44 months from October 1, 2026 to May 31, 2030 with one three-year extension option at market rates, and a $113,574.78 letter of credit is due within 10 days. Why it matters: An estimated $1.1 million of annual savings is meaningful at a clinical-stage de-SPAC that has just completed a 1-for-16 reverse split to defend its listing — that is cash extending the runway without issuing stock, which is the rarest form of financing in this cohort. The small $113,574.78 letter of credit rather than a large cash deposit also preserves liquidity. Downsizing lab space does, however, constrain how much work can be run in-house over the 44-month term.
What changed: On June 17, 2026 the board of Calidi Biotherapeutics, Inc., on the recommendation of the Nominating and Corporate Governance Committee, appointed Dr. Corazon (Corsee) D. Sanders, age 69, as a Class III director with a term expiring at the 2029 annual meeting, and as a member of the Audit Committee. Dr. Sanders is described as a biotechnology executive with more than 30 years of global drug development leadership who serves on the boards of Ultragenyx Pharmaceutical Inc. and Legend Biotech Inc. Why it matters: A single director appointment is not material to the investment case on its own: it changes no financial term, no capital structure and no strategy disclosed here. Its modest relevance is governance capacity, since the appointee joins the Audit Committee and brings drug development and regulatory experience relevant to a clinical-stage company, and public-company board experience at two Nasdaq-listed biotechnology issuers.
What changed: Calidi Biotherapeutics, Inc. supplemented its April 29, 2026 definitive proxy statement for the Annual Meeting of Stockholders to be held June 12, 2026 at 10:00 a.m. Pacific Time by live audio webcast. The supplement amends and restates in its entirety the Vote Required section for Proposal 4, the 2023 Plan Amendment Proposal, on page 49, to correct what the company calls an inadvertent error regarding the treatment of abstentions. Nothing else in the proxy statement is amended, and the board continues to recommend a vote FOR Proposal 4. Why it matters: As corrected, approval requires a majority of the votes cast at the meeting, and broker non-votes AND abstentions have no effect on the outcome; the sentence struck from the section had said abstentions would have the same effect as a vote AGAINST. The direction of that correction is easy to invert, because the redline lives in HTML strike and underline tags: strip the markup and the deleted sentence and its replacement both survive, in sequence, reading as the reverse of what was decided. Holders who have already voted need not vote again.
going-concern doubtnothing moved · 1 with no prior record of ours
- Going-concern doubt
- stated · unchanged
The clause “The Company estimates that based on the Company’s liquidity resources, there is substantial doubt about the Company’s ability to continue as a going concern within 12 months from the date of issuance of these unaudited condensed”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
What changed: Calidi Biotherapeutics, Inc., the successor to First Light Acquisition Group, called its annual meeting for Friday, June 12, 2026 at 10:00 a.m. Pacific Time in a completely virtual format, record date April 17, 2026. Holders are asked to approve a charter amendment allowing the Board, at its discretion, to effect a reverse stock split of the Voting and Non-Voting Common Stock at a ratio between 1-for-2 and 1-for-16. Dr. Eric Poma was appointed Chief Executive Officer and director effective April 22, 2025, previously CEO of Molecular Templates. Mr. Why it matters: A split range as wide as 1-for-2 to 1-for-16 hands the board latitude to compress the share count by up to 94%, with the ratio chosen after the vote - holders approve the outcome without knowing it. Paying a director or officer a percentage fee for personally guaranteeing the company's lease is an unusual related-party arrangement that transfers cash to an insider annually. The First Light trust was released at the de-SPAC.
going-concern doubt, mandate languagenothing moved · 2 with no prior record of ours
- Going-concern doubt
- stated · unchanged
- Mandate language
- we are focusing our development efforts on allogeneic therap…not matched in this filing
The clause …“are dependent on us raising capital and these conditions give rise to substantial doubt over the Company’s ability to continue as a going concern. ● We have incurred significant operating losses since our inception and”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
going-concern doubtnothing moved · 1 with no prior record of ours
- Going-concern doubt
- stated · unchanged
The clause “Management estimates that based on the Company’s liquidity resources, there is substantial doubt about the Company’s ability to continue as a going concern within 12 months from the date of issuance of the unaudited condensed”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
In plain English
Redemption deadlinethe last day to hand shares back for cash
Set by the filing that calls the meeting. Tender after it and the company is under no obligation to pay you the trust value.
Cash in trust / trust per sharethe cash the company is holding for each public share
Filed quarterly in the 10-Q's XBRL. It earns interest between filings, so the figure on a given day is slightly higher than the last filed one — where we show that we label it an estimate.
Accession numberthe SEC's unique id for one filing
Every figure on this page carries the accession of the filing that states it, so you can open the primary document rather than trust us.